➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Dow
Moodys
Medtronic
Johnson and Johnson

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,132,125

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,132,125
Title:Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Inventor(s): Mickle; Travis (Celebration, FL), Guenther; Sven (Coralville, IA), Mickle; Christal (Celebration, FL), Chi; Guochen (Coralville, IA), Kanski; Jaroslaw (Blacksburg, VA), Martin; Andrea K. (Fincastle, VA), Bera; Bindu (Blacksburg, VA)
Assignee: KemPharm, Inc. (Coralville, IA)
Application Number:14/557,570
Patent Claims: 1. A composition comprising acetaminophen and a conjugate, wherein the conjugate is benzoate-hydrocodone (Bz-HC) having the following structure: ##STR00025##

2. The composition of claim 1, wherein the conjugate is used to treat narcotic or opioid abuse; to reduce narcotic or opioid withdrawal; to treat moderate to severe pain; to reduce oral, intranasal or intravenous drug abuse; or to provide oral, intranasal or parenteral drug abuse resistance.

3. The composition of claim 1, wherein the conjugate exhibits an improved AUC and rate of release over time when compared to unconjugated hydrocodone over the same time period; exhibits less variability in the oral PK profile when compared to unconjugated hydrocodone; or has reduced side effects when compared with unconjugated hydrocodone.

4. The composition of claim 1, wherein the conjugate is provided in a dosage form selected from the group consisting of: a tablet, a capsule, a caplet, a suppository, a troche, a lozenge, an oral powder, a solution, an oral film, a thin strip, a slurry, and a suspension.

5. The composition of claim 1, wherein the conjugate is provided in an amount sufficient to provide a therapeutically bioequivalent AUC when compared to unconjugated hydrocodone.

6. The composition of claim 1, wherein the conjugate is provided in an amount sufficient to provide a therapeutically bioequivalent AUC and C.sub.max when compared to an equivalent molar amount of unconjugated hydrocodone.

7. The composition of claim 1, wherein the conjugate is provided in an amount sufficient to provide a therapeutically bioequivalent AUC and a lower C.sub.max when compared to an equivalent molar amount of unconjugated hydrocodone.

8. The composition of claim 1, wherein the conjugate is a salt.

9. The composition of claim 8, wherein the salt is a hydrochloride/chloride.

10. The composition of claim 1, further comprising a biologically acceptable carrier.

11. The composition of claim 1, wherein upon administration, active hydrocodone is released from the conjugate through first-pass metabolism.

12. A method for treating pain in an individual in need thereof comprising the step of orally administering a pharmaceutically effective amount of a composition comprising acetaminophen and a conjugate, wherein the conjugate is benzoate-hydrocodone (Bz-HC) having the following structure: ##STR00026##

13. The method of claim 12, wherein the conjugate exhibits an improved AUC and rate of release over time when compared to unconjugated hydrocodone over the same time period; exhibits less variability in the oral PK profile when compared to unconjugated hydrocodone; or has reduced side effects when compared with unconjugated hydrocodone.

14. The method of claim 12, wherein the composition is provided in a dosage form selected from the group consisting of: a tablet, a capsule, a caplet, a suppository, a troche, a lozenge, an oral powder, a solution, an oral film, a strip, a slurry, and a suspension.

15. The method of claim 12, wherein the conjugate is provided in an amount sufficient to provide a therapeutically bioequivalent AUC when compared to unconjugated hydrocodone.

16. The method of claim 12, wherein the conjugate is provided in an amount sufficient to provide a therapeutically bioequivalent AUC and C.sub.max when compared to an equivalent molar amount of unconjugated hydrocodone.

17. The method of claim 12, wherein the conjugate is provided in an amount sufficient to provide a therapeutically bioequivalent AUC and a lower C.sub.max when compared to an equivalent molar amount of unconjugated hydrocodone.

18. The method of claim 12, wherein the composition is used for treating pain mediated by binding of an opioid primarily to .mu. opioid receptors of the patient.

19. The method of claim 18, wherein the conjugate binds reversibly to the .mu. opioid receptors of the patient.

20. The method of claim 18, wherein the conjugate binds reversibly to the .mu. opioid receptors of the patient without a CNS depressive effect.

21. The method of claim 12, wherein the composition also reduces narcotic or opioid abuse.

22. The method of claim 12, wherein the composition also reduces narcotic or opioid withdrawal.

23. The method of claim 12, wherein the composition also reduces oral, intranasal or intravenous narcotic or opioid abuse.

24. The method of claim 12, wherein the composition also provides oral, intranasal or parenteral non corticoid opioid abuse resistance.

25. A pharmaceutical kit comprising a specified amount of individual doses in a package containing a pharmaceutically effective amount of acetaminophen and a conjugate, wherein the conjugate is benzoate-hydrocodone (Bz-HC) having the following structure: ##STR00027##

26. The pharmaceutical kit of claim 25, wherein the kit further comprises instructions for use of the kit in a method for treating pain.

27. The pharmaceutical kit of claim 25, wherein the kit further comprises instructions for use of the kit in a method for treating narcotic or opioid withdrawal symptoms.

28. The pharmaceutical kit of claim 25, wherein the kit further comprises instructions for use of the kit in a method for reducing narcotic or opioid abuse.

29. The pharmaceutical kit of claim 25, wherein the specified amount of individual doses comprise from about 1 to about 100 individual dosages.

30. The pharmaceutical kit of claim 25, wherein the individual doses comprise at least about 0.5 mg of the conjugate.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
McKinsey
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.